Verition Fund Management LLC Invests $134,000 in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Verition Fund Management LLC bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 37,643 shares of the company’s stock, valued at approximately $134,000. Verition Fund Management LLC owned 0.06% of Fulcrum Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in FULC. Dimensional Fund Advisors LP boosted its position in Fulcrum Therapeutics by 13.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock valued at $9,182,000 after buying an additional 176,114 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after acquiring an additional 393,202 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Fulcrum Therapeutics in the second quarter valued at about $3,084,000. Marshall Wace LLP boosted its holdings in Fulcrum Therapeutics by 47.7% in the second quarter. Marshall Wace LLP now owns 333,161 shares of the company’s stock valued at $2,066,000 after purchasing an additional 107,588 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Fulcrum Therapeutics during the 2nd quarter valued at approximately $1,158,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on FULC. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. HC Wainwright reissued a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Up 11.6 %

FULC opened at $4.42 on Tuesday. The company’s 50-day moving average price is $3.52 and its 200 day moving average price is $5.89. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $13.70. The firm has a market cap of $238.41 million, a price-to-earnings ratio of -14.26 and a beta of 2.14.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.